Editing Tacrine (section)

{{short description|Chemical compound}}
{{cs1 config|name-list-style=vanc|display-authors=6}}
{{Infobox drug
| Watchedfields = changed
| verifiedrevid = 470476624
| IUPAC_name = 1,2,3,4-Tetrahydroacridin-9-amine
| image = Tacrine2DACS.svg
| image_class = skin-invert-image
| width = 150
| image2 = Tacrine3Dan.gif
| width2 = 200
<!--Clinical data-->
| tradename = Cognex
| Drugs.com = {{drugs.com|monograph|tacrine-hydrochloride}}
| MedlinePlus = a693039
| pregnancy_AU = C
| pregnancy_US = C
| legal_AU = S4
| legal_BR = C1
| legal_BR_comment = <ref>{{Cite web |author=Anvisa |author-link=Brazilian Health Regulatory Agency |date=2023-03-31 |title=RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial |trans-title=Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control|url=https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |url-status=live |archive-url=https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 |archive-date=2023-08-03 |access-date=2023-08-16 |publisher=[[Diário Oficial da União]] |language=pt-BR |publication-date=2023-04-04}}</ref>
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = Oral, rectal
<!--Pharmacokinetic data-->
| bioavailability = 2.4–36% (oral)
| protein_bound = 55%
| metabolism = Hepatic ([[CYP1A2]])
| elimination_half-life = 2–4 hours
| excretion = Renal
<!--Identifiers-->
| IUPHAR_ligand = 6687
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 321-64-2
| ATC_prefix = N06
| ATC_suffix = DA01
| ATC_supplemental = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00382
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 1859
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 4VX7YNB537
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 45980
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 95
| PDB_ligand = THA
<!--Chemical data-->
| C=13 | H=14 | N=2
| melting_point = 183
| boiling_point = 358
| smiles = n1c3c(c(c2c1cccc2)N)CCCC3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YLJREFDVOIBQDA-UHFFFAOYSA-N
}}

'''Tacrine''' is a centrally acting [[anticholinesterase inhibitor|acetylcholinesterase inhibitor]] and indirect [[cholinergic]] agonist ([[parasympathomimetic]]). It was the first centrally acting cholinesterase inhibitor approved for the treatment of [[Alzheimer's disease]], and was marketed under the trade name '''Cognex'''. Tacrine was first synthesised by [[Adrien Albert]] at the [[University of Sydney]] in 1949. It also acts as a [[histamine N-methyltransferase]] inhibitor.<ref>{{cite journal | vauthors = Taraschenko OD, Barnes WG, Herrick-Davis K, Yokoyama Y, Boyd DL, Hough LB | title = Actions of tacrine and galanthamine on histamine-N-methyltransferase | journal = Methods and Findings in Experimental and Clinical Pharmacology | volume = 27 | issue = 3 | pages = 161–165 | date = April 2005 | pmid = 15834447 | doi = 10.1358/mf.2005.27.3.890872 }}</ref>